8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Mar 16, 2026·SEC
Relay Therapeutics, Inc.(RLAY)Earnings, Financials & Key Ratios
RLAY•NASDAQ
Price updated Jun 19, 2026
AboutRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$15M+53.4%
- EBITDA-$299M+18.5%
- Net Income-$276M+18.1%
- EPS (Diluted)-1.61+31.8%
- Gross Margin76.83%-23.2%
- EBITDA Margin-1948.43%+46.9%
- Operating Margin-1971.59%+47.0%
- Net Margin-1800.58%+46.6%
- ROE-41.12%+6.9%
RLAY Key Insights
Relay Therapeutics, Inc. (RLAY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 93 (top 7%)
✗Weaknesses
- ✗Profits declining 39.5% over 5 years
- ✗Negative free cash flow
- ✗Sales declining 28.6% over 5 years
- ✗Shares diluted 20.1% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RLAY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RLAY Price & Volume
Relay Therapeutics, Inc. (RLAY) stock price & volume — 10-year historical chart
Loading chart...
RLAY Growth Metrics
Relay Therapeutics, Inc. (RLAY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-28.58%
3 Years123.2%
TTM39.04%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM29.6%
Return on Capital
10 Years-30.23%
5 Years-39.9%
3 Years-42.89%
Last Year-42.75%
RLAY Recent Earnings
Relay Therapeutics, Inc. (RLAY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (63%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.41-17.1%
$0.35
Rev
$3M-46.2%
$6M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.32+15.8%
$0.38
Rev
$7M+41.0%
$5M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.43-10.3%
$0.39
Rev
—
$5M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.41+16.3%
$0.49
Rev
$677,000+4637.6%
$14,290
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.41vs $0.35-17.1% | $3Mvs $6M-46.2% |
| Q1 2026 | Feb 26, 2026 | $0.32vs $0.38+15.8% | $7Mvs $5M+41.0% |
| Q4 2025 | Nov 6, 2025 | $0.43vs $0.39-10.3% | —vs $5M |
| Q3 2025 | Aug 7, 2025 | $0.41vs $0.49+16.3% | $677,000vs $14,290+4637.6% |
Based on last 12 quarters of dataView full earnings history →
RLAY Peer Comparison
Relay Therapeutics, Inc. (RLAY) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 ERAS | 4.25B | 13.67 | -31.07 | -77.01% | 0.14 | |||
 MRUS | 6.83B | 90.00 | -26.87 | -12.38% | -6.54% | -50.62% | 0.02 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 AUPH | 2.12B | 16.46 | 7.95 | 20.38% | 99.97% | 64.48% | 0.13 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 |
Compare RLAY vs Peers
Relay Therapeutics, Inc. (RLAY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RLAY Income Statement
Relay Therapeutics, Inc. (RLAY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 82.65M | 3.03M | 1.38M | 25.55M | 10.01M | 15.36M | 10.68M |
Revenue Growth % | - | - | - | -96.34% | -54.41% | 1749.82% | -60.83% | 53.44% | 39.04% |
Cost of Goods Sold | 2.15M | 2.85M | 3.55M | 0 | 0 | 0 | 0 | 3.56M | 599K |
COGS % of Revenue | - | - | 4.29% | - | - | - | - | 23.17% | - |
Gross Profit | -2.15M▲ 0% | -2.85M▼ 32.1% | 79.11M▲ 2880.5% | 3.03M▼ 96.2% | 1.38M▼ 54.4% | 25.55M▲ 1749.8% | 10.01M▼ 60.8% | 11.8M▲ 17.9% | 7.08M▲ 0% |
Gross Margin % | - | - | 95.71% | 100% | 100% | 100% | 100% | 76.83% | 66.29% |
Gross Profit Growth % | - | -32.08% | 2880.49% | -96.17% | -54.41% | 1749.82% | -60.83% | 17.9% | - |
Operating Expenses | 49.89M | 84.05M | 134.9M | 367.73M | 300.66M | 398.55M | 382.48M | 314.54M | 306.54M |
OpEx % of Revenue | - | - | 163.21% | 12140.21% | 21770.89% | 1560.11% | 3822.07% | 2048.43% | - |
Selling, General & Admin | 8.86M | 13.74M | 38.59M | 57.39M | 65.98M | 74.95M | 76.59M | 56.71M | 49.75M |
SG&A % of Revenue | - | - | 46.69% | 1894.55% | 4777.55% | 293.39% | 765.38% | 369.33% | - |
Research & Development | 41.03M | 70.31M | 99.86M | 172.65M | 246.35M | 330.02M | 319.09M | 261.38M | 258.14M |
R&D % of Revenue | - | - | 120.82% | 5699.9% | 17838.88% | 1291.86% | 3188.66% | 1702.27% | - |
Other Operating Expenses | -9K | 0 | -3.55M | 137.69M | -11.68M | -6.42M | -13.21M | -3.56M | -1000K |
Operating Income | -49.89M▲ 0% | -84.05M▼ 68.5% | -55.8M▲ 33.6% | -364.7M▼ 553.6% | -299.27M▲ 17.9% | -373M▼ 24.6% | -372.47M▲ 0.1% | -302.74M▲ 18.7% | -296.46M▲ 0% |
Operating Margin % | - | - | -67.51% | -12040.21% | -21670.89% | -1460.11% | -3722.07% | -1971.59% | -2776.61% |
Operating Income Growth % | - | -68.47% | 33.61% | -553.63% | 17.94% | -24.63% | 0.14% | 18.72% | - |
EBITDA | -47.73M | -81.2M | -52.25M | -360.77M | -295.14M | -367.73M | -367M | -299.18M | -297.67M |
EBITDA Margin % | - | - | -63.21% | -11910.63% | -21371.83% | -1439.49% | -3667.47% | -1948.43% | -2787.93% |
EBITDA Growth % | - | -70.11% | 35.66% | -590.51% | 18.19% | -24.59% | 0.2% | 18.48% | 17.7% |
D&A (Non-Cash Add-back) | 2.15M | 2.85M | 3.55M | 3.92M | 4.13M | 5.27M | 5.46M | 3.56M | -1.21M |
EBIT | -48.78M | -84.05M | -55.8M | -227.01M | -310.95M | -379.42M | -385.67M | -276.48M | -212.13M |
Net Interest Income | 0 | 8.8M | 3.4M | 830K | 8.79M | 31.05M | 34.75M | 27.04M | 19.22M |
Interest Income | 1.11M | 8.8M | 3.4M | 830K | 8.79M | 31.05M | 34.75M | 27.04M | 24.57M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.1M | 8.74M | 3.38M | 826K | 8.77M | 31.03M | 34.76M | 26.26M | 23.75M |
Pretax Income | -48.78M▲ 0% | -75.31M▼ 54.4% | -52.41M▲ 30.4% | -363.87M▼ 594.3% | -290.51M▲ 20.2% | -341.97M▼ 17.7% | -337.71M▲ 1.2% | -276.48M▲ 18.1% | -272.7M▲ 0% |
Pretax Margin % | - | - | -63.41% | -12012.94% | -21036.13% | -1338.66% | -3374.72% | -1800.58% | -2554.14% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -48.78M▲ 0% | -66.5M▼ 36.3% | -52.41M▲ 21.2% | -363.87M▼ 594.3% | -290.51M▲ 20.2% | -341.97M▼ 17.7% | -337.71M▲ 1.2% | -276.48M▲ 18.1% | -272.7M▲ 0% |
Net Margin % | - | - | -63.41% | -12012.94% | -21036.13% | -1338.66% | -3374.72% | -1800.58% | -2554.14% |
Net Income Growth % | - | -36.32% | 21.19% | -594.25% | 20.16% | -17.72% | 1.25% | 18.13% | 18.2% |
Net Income (Continuing) | -48.78M | -75.31M | -52.41M | -363.87M | -290.51M | -341.97M | -337.71M | -276.48M | -272.7M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -19.63▲ 0% | -15.53▲ 20.9% | -2.56▲ 83.5% | -3.82▼ 49.2% | -2.59▲ 32.2% | -2.79▼ 7.7% | -2.36▲ 15.4% | -1.61▲ 31.8% | -1.52▲ 0% |
EPS Growth % | - | 20.89% | 83.52% | -49.22% | 32.2% | -7.72% | 15.41% | 31.78% | 29.6% |
EPS (Basic) | -19.63 | -15.53 | -2.56 | -3.82 | -2.59 | -2.79 | -2.36 | -1.61 | - |
Diluted Shares Outstanding | 2.49M | 4.28M | 90.19M | 95.14M | 112.23M | 122.58M | 142.87M | 171.59M | 179.85M |
Basic Shares Outstanding | 2.49M | 4.28M | 90.05M | 95.14M | 112.23M | 122.58M | 142.87M | 171.59M | 179.85M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
RLAY Balance Sheet
Relay Therapeutics, Inc. (RLAY) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 424.1M | 360.54M | 770.1M | 976.24M | 1.02B | 770.1M | 809.2M | 578.28M | 658.46M |
Cash & Short-Term Investments | 421.5M | 355.82M | 678.06M | 958.07M | 998.92M | 750.09M | 781.32M | 554.52M | 204.59M |
Cash Only | 421.5M | 41.95M | 447.65M | 280.12M | 998.92M | 143.74M | 124.29M | 84.02M | 204.59M |
Short-Term Investments | 0 | 313.86M | 230.41M | 677.95M | 0 | 606.35M | 657.04M | 470.5M | 0 |
Accounts Receivable | 0 | 0 | 82.65M | 4.94M | 5.22M | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | 365 | 595.28 | 1.38K | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 12.11M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 1.76M | 3.26M | 3.31M | 10.53M | 23.76M | 453.87M |
Total Non-Current Assets | 4.51M | 32.53M | 29.73M | 32.2M | 80.27M | 73.88M | 62.09M | 43.05M | 41.15M |
Property, Plant & Equipment | 3.63M | 31.65M | 28.83M | 27.32M | 75.39M | 68.87M | 57.67M | 41.72M | 39.81M |
Fixed Asset Turnover | - | - | 2.87x | 0.11x | 0.02x | 0.37x | 0.17x | 0.37x | 0.25x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 2.3M | 2.3M | 2.3M | 2.3M | 0 | 0 |
Long-Term Investments | 878K | 0 | 0 | 0 | 2.58M | 2.71M | 0 | 1.34M | 1.34M |
Other Non-Current Assets | 0 | 878K | 900K | 2.58M | 2.58M | 0 | 2.12M | 0 | 1.34M |
Total Assets | 428.61M▲ 0% | 393.07M▼ 8.3% | 799.83M▲ 103.5% | 1.01B▲ 26.1% | 1.1B▲ 9.1% | 843.98M▼ 23.3% | 871.3M▲ 3.2% | 621.33M▼ 28.7% | 699.61M▲ 0% |
Asset Turnover | - | - | 0.10x | 0.00x | 0.00x | 0.03x | 0.01x | 0.02x | 0.02x |
Asset Growth % | - | -8.29% | 103.48% | 26.08% | 9.06% | -23.26% | 3.24% | -28.69% | -74.79% |
Total Current Liabilities | 6.87M | 11.99M | 13.63M | 24.32M | 63.71M | 30.27M | 50.73M | 25.58M | 29.75M |
Accounts Payable | 4.71M | 6.99M | 6.35M | 8.28M | 10.58M | 9.21M | 14.1M | 7.71M | 4.1M |
Days Payables Outstanding | 797.27 | 896.91 | 653.17 | - | - | - | - | 790.65 | 3.01K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.77M | 3.89M |
Deferred Revenue (Current) | 1.86M | 0 | 0 | 248K | 0 | 0 | 7.68M | 0 | 0 |
Other Current Liabilities | 118K | 333K | 197K | 989K | 26.15M | 1.91M | 2.1M | 14.11M | 21.76M |
Current Ratio | 61.78x | 30.08x | 56.49x | 40.14x | 16.00x | 25.44x | 15.95x | 22.61x | 22.13x |
Quick Ratio | 61.78x | 30.08x | 56.49x | 40.14x | 15.81x | 25.44x | 15.95x | 22.61x | 22.13x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 532.67M | 561.52M | 22.9M | 86.31M | 85.84M | 61.71M | 42.77M | 28.69M | 27.68M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27.68M |
Capital Lease Obligations | 0 | 23.58M | 22.9M | 21.06M | 53.47M | 48.5M | 42.77M | 28.69M | 89.04M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 532.67M | 537.94M | 3K | 65.26M | 32.38M | 13.21M | 0 | 0 | 0 |
Total Liabilities | 539.54M | 573.51M | 36.54M | 110.64M | 149.55M | 91.98M | 93.5M | 54.27M | 57.43M |
Total Debt | 178K | 24.83M | 24.42M | 22.9M | 57.74M | 53.47M | 48.5M | 32.46M | 31.57M |
Net Debt | -421.33M | -17.12M | -423.22M | -257.22M | -941.17M | -90.27M | -75.78M | -51.56M | -173.02M |
Debt / Equity | - | - | 0.03x | 0.03x | 0.06x | 0.07x | 0.06x | 0.06x | 0.05x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.58x |
Interest Coverage | - | - | - | - | - | - | - | - | - |
Total Equity | -110.93M▲ 0% | -180.44M▼ 62.7% | 763.29M▲ 523.0% | 897.81M▲ 17.6% | 950.22M▲ 5.8% | 752M▼ 20.9% | 777.79M▲ 3.4% | 567.06M▼ 27.1% | 642.18M▲ 0% |
Equity Growth % | - | -62.66% | 523.02% | 17.62% | 5.84% | -20.86% | 3.43% | -27.09% | -67.95% |
Book Value per Share | -44.64 | -42.15 | 8.46 | 9.44 | 8.47 | 6.13 | 5.44 | 3.30 | 3.57 |
Total Shareholders' Equity | -110.93M | -180.44M | 763.29M | 897.81M | 950.22M | 752M | 777.79M | 567.06M | 642.18M |
Common Stock | 3K | 4K | 90K | 109K | 121K | 127K | 168K | 168K | 182K |
Retained Earnings | -114.18M | -189.48M | -404.23M | -768.1M | -1.06B | -1.4B | -1.74B | -2.01B | -2.09B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -4.65M | 325K | 64K | -1.09M | -10.42M | -196K | -991K | 733K | -172K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RLAY Cash Flow Statement
Relay Therapeutics, Inc. (RLAY) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -44.13M | -66.13M | -102.49M | -74.41M | -229.49M | -300.32M | -249.11M | -235.46M | -213.36M |
Operating CF Margin % | - | - | -124% | -2456.45% | -16617.67% | -1175.59% | -2489.33% | -1533.41% | - |
Operating CF Growth % | - | -49.84% | -54.97% | 27.4% | -208.43% | -30.86% | 17.05% | 5.48% | 85.98% |
Net Income | -48.78M | -75.31M | -52.41M | -363.87M | -290.51M | -341.97M | -337.71M | -276.48M | -272.7M |
Depreciation & Amortization | 2.15M | 2.85M | 3.55M | 3.92M | 4.13M | 5.27M | 5.46M | -1.39M | -180K |
Stock-Based Compensation | 2.89M | 4.46M | 31.96M | 48.45M | 56.14M | 86.03M | 94.14M | 62.42M | 53.63M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 9K | -2.44M | -416K | 139.74M | -10.49M | -17.18M | -25.62M | 3.3M | 14.12M |
Working Capital Changes | -400K | 4.31M | -85.17M | 97.34M | 11.25M | -32.46M | 14.62M | -23.31M | -8.22M |
Change in Receivables | 0 | 0 | -75M | 77.79M | 97K | 5.22M | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | -10.33M | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.23M | 3M | -410K | 930K | 1.99M | -2.39M | 0 | -11.44M | -4.33M |
Cash from Investing | -1.68M | -319.02M | 81.67M | -479.51M | -188.75M | 257.63M | -41.08M | 192.8M | 183.24M |
Capital Expenditures | -1.69M | -8M | -1.93M | -3.47M | -9.06M | -4.13M | -2.02M | -410K | -26K |
CapEx % of Revenue | - | - | 2.34% | 114.59% | 656.19% | 16.15% | 20.17% | 2.67% | 0.24% |
Acquisitions | 7K | 0 | -83.6M | -25.3M | 179.68M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 7K | 20K | 83.6M | 0 | -179.68M | 0 | 0 | 0 | 0 |
Cash from Financing | 394.97M | 5.61M | 426.51M | 388.09M | 289.91M | 34.75M | 270.15M | 1.6M | 140.39M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 394.25M | 4.99M | 425.29M | 382.21M | 284.74M | 30.28M | 265.89M | 1.6M | 1.6M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -82K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 653K |
Other Financing | 717K | 613K | 1.22M | 5.88M | 5.17M | 4.47M | 4.26M | 0 | 138.78M |
Net Change in Cash | 349.16M▲ 0% | -379.55M▼ 208.7% | 405.69M▲ 206.9% | -165.83M▼ 140.9% | -128.32M▲ 22.6% | -7.93M▲ 93.8% | -20.04M▼ 152.7% | -41.05M▼ 104.9% | 110.26M▲ 0% |
Free Cash Flow | -45.82M▲ 0% | -74.14M▼ 61.8% | -104.42M▼ 40.9% | -77.88M▲ 25.4% | -238.55M▼ 206.3% | -304.44M▼ 27.6% | -251.13M▲ 17.5% | -235.87M▲ 6.1% | -213.38M▲ 0% |
FCF Margin % | - | - | -126.33% | -2571.05% | -17273.86% | -1191.74% | -2509.49% | -1536.08% | -1998.53% |
FCF Growth % | - | -61.79% | -40.85% | 25.42% | -206.32% | -27.62% | 17.51% | 6.08% | 21.73% |
FCF per Share | -18.44 | -17.32 | -1.16 | -0.82 | -2.13 | -2.48 | -1.76 | -1.37 | -1.19 |
FCF Conversion (FCF/Net Income) | 0.90x | 0.99x | 1.96x | 0.20x | 0.79x | 0.88x | 0.74x | 0.85x | 0.78x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RLAY Key Ratios
Relay Therapeutics, Inc. (RLAY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -17.98% | -43.81% | -31.44% | -40.18% | -44.15% | -41.12% | -43.94% |
Return on Invested Capital (ROIC) | - | -58.73% | -55.78% | -69.1% | -83.41% | -40.97% | -37.3% | -41.95% |
Gross Margin | - | 95.71% | 100% | 100% | 100% | 100% | 76.83% | 66.29% |
Net Margin | - | -63.41% | -12012.94% | -21036.13% | -1338.66% | -3374.72% | -1800.58% | -2554.14% |
Debt / Equity | - | 0.03x | 0.03x | 0.06x | 0.07x | 0.06x | 0.06x | 0.05x |
FCF Conversion | 0.99x | 1.96x | 0.20x | 0.79x | 0.88x | 0.74x | 0.85x | 0.78x |
Revenue Growth | - | - | -96.34% | -54.41% | 1749.82% | -60.83% | 53.44% | 39.04% |
Related:RLAY Dividend History·RLAY Revenue History·RLAY Price History·RLAY P/E History·RLAY Financial Ratios·RLAY Institutional Holders
RLAY SEC Filings & Documents
Relay Therapeutics, Inc. (RLAY) SEC filings — annual & quarterly reports (10-K, 10-Q)
RLAY Frequently Asked Questions
Relay Therapeutics, Inc. (RLAY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Relay Therapeutics, Inc. (RLAY) reported $10.7M in revenue for fiscal year 2025.
Relay Therapeutics, Inc. (RLAY) grew revenue by 53.4% over the past year. This is strong growth.
Relay Therapeutics, Inc. (RLAY) reported a net loss of $272.7M for fiscal year 2025.
Dividend & Returns
Relay Therapeutics, Inc. (RLAY) has a return on equity (ROE) of -41.1%. Negative ROE indicates the company is unprofitable.
Relay Therapeutics, Inc. (RLAY) had negative free cash flow of $213.4M in fiscal year 2025, likely due to heavy capital investments.